Research Article
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
Table 4
Differences of a gene in patients with different curative effects after neoadjuvant chemotherapy.
| | Pathway | Gene count | Gene |
| | Upregulated | Neutrophil | 1 | CA4 | | Helper_T_cells | 1 | GATA3 | | Tumor_marker | 1 | KRT7 | | Lymphocyte_development | 1 | IKZF2 | | Chemokine_signaling | 1 | VEGFA |
| | Downregulated | Adhesion_migration | 2 | ADGRE5, CD53 | | Tumor_marker | 2 | MMP2, TWIST1 | | Innate_immune_response | 2 | C1QA, C1QB | | Lymphocyte_infiltrate | 2 | CCL21, CCL18 | | Antigen_processing | 1 | HLA-DPB1 | | Macrophage | 1 | CD163 | | Dendritic_cell_macrophage | 1 | CD209 | | Cytokine_signaling | 1 | HGF | | Leukocyte_inhibition | 1 | LST1 | | Checkpoint_pathway | 1 | TNFSF14 |
|
|
